anastrozole has been researched along with Carcinoma, Intraductal, Noninfiltrating in 13 studies
Carcinoma, Intraductal, Noninfiltrating: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Postmenopausal women at increased risk of developing breast cancer were recruited and were randomly assigned (1:1) to either anastrozole (1 mg per day, oral) or matching placebo daily for 5 years." | 9.34 | Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Evans, DG; Forbes, JF; Howell, A; Loibl, S; Mansel, RE; Sestak, I, 2020) |
| "Anastrozole reduces breast cancer risk in women at high risk, but implementing preventive therapy in clinical practice is difficult." | 9.27 | Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. ( Cuzick, J; Forbes, JF; Howell, A; Sestak, I; Smith, SG, 2018) |
| "Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women." | 9.19 | Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Knox, J; Mansel, RE; Palva, T; Roche, N; Saunders, C; Sestak, I; von Minckwitz, G, 2014) |
| "The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk." | 5.35 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008) |
| " Postmenopausal women at increased risk of developing breast cancer were recruited and were randomly assigned (1:1) to either anastrozole (1 mg per day, oral) or matching placebo daily for 5 years." | 5.34 | Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Evans, DG; Forbes, JF; Howell, A; Loibl, S; Mansel, RE; Sestak, I, 2020) |
| "Anastrozole reduces breast cancer risk in women at high risk, but implementing preventive therapy in clinical practice is difficult." | 5.27 | Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. ( Cuzick, J; Forbes, JF; Howell, A; Sestak, I; Smith, SG, 2018) |
| "Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women." | 5.19 | Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Knox, J; Mansel, RE; Palva, T; Roche, N; Saunders, C; Sestak, I; von Minckwitz, G, 2014) |
| "This study piloted a DA booklet for a high priority breast cancer prevention trial, IBIS-II DCIS, which compares the efficacy of an aromatase inhibitor (anastrozole) with tamoxifen in women who have had surgery for ductal carcinoma in situ (DCIS)." | 5.13 | Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS). ( Boyle, F; Butow, P; Coates, A; Forbes, JF; Juraskova, I; Lopez, A; McCarthy, N; Reaby, L; Seccombe, M, 2008) |
| "Although tamoxifen has been the gold standard of HT for breast cancer, results of ongoing trials assessing the newer HTs as initial, neoadjuvant, adjuvant, and chemopreventive therapies may substantially change our current clinical practice patterns." | 4.81 | Evolving uses of hormonal agents for breast cancer therapy. ( Cummings, FJ, 2002) |
| "The management of ductal carcinoma in situ (DCIS) with endocrine therapy remains controversial." | 2.66 | Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis. ( Drokow, EK; Li, Z; Liu, J; Ma, X; Ren, J; Shao, S; Shi, X; Tan, L; Xue, C; Yan, Y; Zhang, L; Zhang, X; Zhang, Y, 2020) |
| "However, concern for under- or over-treatment of DCIS has led many surgeons to question historically standardized approaches and instead begin to tailor treatment based on individual prognostic indicators." | 2.52 | Ductal Carcinoma In Situ: Treatment Update and Current Trends. ( Kuerer, H; Mitchell, KB, 2015) |
| "The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk." | 1.35 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Kantor, O | 1 |
| King, TA | 1 |
| Jones, A | 1 |
| Glass, C | 1 |
| Leonard, SJ | 1 |
| Ogayo, ER | 1 |
| Mayer, EL | 1 |
| Chavez-MacGregor, M | 1 |
| Newman, LA | 1 |
| Freedman, RA | 1 |
| Mittendorf, EA | 1 |
| Cuzick, J | 4 |
| Sestak, I | 3 |
| Forbes, JF | 4 |
| Dowsett, M | 2 |
| Cawthorn, S | 2 |
| Mansel, RE | 2 |
| Loibl, S | 1 |
| Bonanni, B | 2 |
| Evans, DG | 1 |
| Howell, A | 3 |
| Smith, SG | 1 |
| Yan, Y | 1 |
| Zhang, L | 1 |
| Tan, L | 1 |
| Ma, X | 1 |
| Zhang, Y | 1 |
| Shao, S | 1 |
| Liu, J | 1 |
| Xue, C | 1 |
| Li, Z | 1 |
| Zhang, X | 1 |
| Drokow, EK | 1 |
| Shi, X | 1 |
| Ren, J | 1 |
| Cameron, DA | 1 |
| Knox, J | 1 |
| Saunders, C | 1 |
| Roche, N | 1 |
| von Minckwitz, G | 1 |
| Palva, T | 1 |
| Mitchell, KB | 1 |
| Kuerer, H | 1 |
| Saha, P | 1 |
| Amico, AL | 1 |
| Olopade, OI | 1 |
| Juraskova, I | 1 |
| Butow, P | 1 |
| Lopez, A | 1 |
| Seccombe, M | 1 |
| Coates, A | 1 |
| Boyle, F | 1 |
| McCarthy, N | 1 |
| Reaby, L | 1 |
| Cummings, FJ | 1 |
| Thornton, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| International Breast Cancer Intervention Study[NCT00078832] | Phase 3 | 3,864 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| International Breast Cancer Intervention Study II (IBIS-II) (DCIS)[NCT00072462] | Phase 3 | 2,980 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Effects of Progressive Relaxation Training on Artralgia, Quality of Life and Emotional Status in Breast Cancer Patients Receiving Aromatatase Inhibitor Therapy[NCT04163692] | 44 participants (Actual) | Interventional | 2019-10-25 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for anastrozole and Carcinoma, Intraductal, Noninfiltrating
| Article | Year |
|---|---|
Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2020 |
Ductal Carcinoma In Situ: Treatment Update and Current Trends.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2015 |
Evolving uses of hormonal agents for breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2002 |
5 trials available for anastrozole and Carcinoma, Intraductal, Noninfiltrating
| Article | Year |
|---|---|
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.
Topics: Anastrozole; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Ethnicity; Female; Humans; T | 2023 |
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, D | 2020 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; | 2008 |
5 other studies available for anastrozole and Carcinoma, Intraductal, Noninfiltrating
| Article | Year |
|---|---|
Breast cancer chemoprevention: little progress in practice?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2014 |
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carc | 2016 |
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; | 2008 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2004 |
Anastrozole as a preventive agent in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2003 |